Pays: Canada
Langue: anglais
Source: Health Canada
BICALUTAMIDE
DOMINION PHARMACAL
L02BB03
BICALUTAMIDE
50MG
TABLET
BICALUTAMIDE 50MG
ORAL
100
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0127996001; AHFS:
APPROVED
2006-06-16
PRODUCT MONOGRAPH PR DOM-BICALUTAMIDE Bicalutamide Tablets, House Standard 50 mg NON-STEROIDAL ANTIANDROGEN DOMINION PHARMACAL 6111 Royalmount Ave., Suite 100 Montréal, Canada H4P 2T4 Date of Revision: March 15, 2017 Submission Control No.: 202528 _ _ _Dom-BICALUTAMIDE Product Monograph _ _ _ _Page 2 of 30 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................8 DRUG INTERACTIONS ..................................................................................................11 DOSAGE AND ADMINISTRATION ..............................................................................12 OVERDOSAGE ................................................................................................................13 ACTION AND CLINICAL PHARMACOLOGY ............................................................13 STORAGE AND STABILITY ..........................................................................................14 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................14 PART II: SCIENTIFIC INFORMATION ...............................................................................15 PHARMACEUTICAL INFORMATION ..........................................................................15 CLINICAL TRIALS ..........................................................................................................16 DETAILED PHARMACOLOGY ............................................. Lire le document complet